5:52 PM
 | 
Jul 23, 2013
 |  BC Extra  |  Company News

Lilly licenses preclinical OA compound to Transition

Eli Lilly and Co. (NYSE:LLY) granted Transition Therapeutics Inc. (TSX:TTH; NASDAQ:TTHI) exclusive, worldwide rights to develop and commercialize a preclinical compound in development for osteoarthritis pain. In...

Read the full 125 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >